PharmaLogic Secures Majority Stake in Agilera Pharma AS to Enhance Global Holdings

PharmaLogic Strengthens Its Global Presence with Agilera Pharma AS Acquisition



PharmaLogic Holdings Corp., a prominent entity in the field of contract development and manufacturing organizations (CDMO) specializing in radiopharmaceuticals, announced the completion of its acquisition of a majority stake in Agilera Pharma AS, as per their declarations earlier this year. This strategic move marks a pivotal moment in PharmaLogic's ambition to create a fully integrated global CDMO platform that focuses on radiopharmaceutical therapeutics.

Broadening Capabilities and Market Reach


The acquisition is a game-changer, significantly enhancing PharmaLogic's capabilities in the development, manufacturing, and worldwide distribution of both commercial and clinical therapeutic radiopharmaceuticals. This not only broadens the company's geographic reach but also expands its operational scale, allowing for a more robust infrastructure within the rapidly advancing field of radiopharmaceuticals.

"Adding Agilera’s expertise into our fold is a significant milestone that aligns perfectly with our expansion strategy into radiopharmaceutical therapeutics," stated Etienne Montagut, President and CEO of PharmaLogic. He highlighted that Agilera's extensive experience in providing and distributing commercial radiopharmaceutical therapies has proven successful, reaching over 30 countries globally. This acquisition establishes a strong foundation for enhanced end-to-end solutions in radiopharmaceutical manufacturing.

The Expertise of Agilera Pharma AS


Founded as a subsidiary of the Institute for Energy Technology (IFE) in Norway in 2023, Agilera Pharma AS boasts a workforce of 140 skilled employees who contribute to its three primary business areas:
1. CDMO Development: Partnering for innovative radiopharmaceuticals from the early phases of development to clinical production, tailored specifically to client needs.
2. CMO Production and Distribution: Mass production and distribution of a commercial radiopharmaceutical therapy in compliance with Norwegian Medicines Agency permits and GMP standards, servicing over 30 countries.
3. Wholesaler and Distribution: Functioning as the national wholesaler of radiopharmaceuticals in Norway, equipped with a central pharmacy and an effective logistics center for distributing materials worldwide.

This diversified expertise positions Agilera Pharma AS as a leader in the radiopharmaceutical sector, making it an ideal addition to PharmaLogic's already expansive portfolio.

Commitment to Quality and Regulation


PharmaLogic’s robust operational base spans over 45 facilities across various regions including the U.S., Puerto Rico, Canada, and Norway. The organization prides itself on a commitment to meeting the highest quality and regulatory standards in the industry. In the area of diagnostics, their rapidly growing business leverages advanced technologies that improve patient access to novel diagnostics in oncology, cardiology, and neurology.

Moreover, PharmaLogic is notable for being the only cGMP-compliant CDMO currently engaged in the production and distribution of commercial therapeutics in radiopharmaceuticals, catering to markets in more than 30 countries worldwide.

Future Goals and Strategic Partnerships


PharmaLogic aims to enable wider patient access to radiopharmaceuticals through strategic development partnerships with industry innovators, thus advancing the future of this critical field. Their collaboration with Agilera is anticipated to cultivate new opportunities for innovation and growth within the global healthcare landscape.

As the demand for specialized therapeutic options increases, PharmaLogic’s expansion via the Agilera acquisition is set to reinforce their position as a pivotal player in the treatment and diagnostic landscape of radiopharmaceuticals. By committing to the development of safer and more effective treatment options, PharmaLogic continues to lead the charge in a growing industry that is transforming patient care worldwide. For more information, engage with PharmaLogic through their website radiopharmacy.com or follow them on LinkedIn.

Conclusion


This acquisition signifies not just an expansion of business capabilities but a steadfast commitment to the evolution of healthcare solutions. As PharmaLogic and Agilera forge a path towards innovative radiopharmaceutical applications, stakeholders in the healthcare sector eagerly anticipate the promising advancements that lie ahead.

About PharmaLogic Holdings Corp.
PharmaLogic operates at the leading edge of contract development and manufacturing for diagnostic and therapeutic radiopharmaceuticals. Their legacy is supported by vast industry expertise and strategic aspirations aimed at transforming the therapeutic landscape.

About IFE
Founded in 1948, IFE is a research institute focusing on nuclear energy research, with historical contributions to radiopharmaceutical development that have significantly influenced diagnostic and clinical practices in cancer treatment and beyond.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.